All News

Cancer is a dark place, but we can bring light to it.

The Food and Drug Administration (FDA) will not be meeting the Jan. 12, 2024 approval deadline for zolbetuximab to treat certain patients with gastric or gastroesophageal junction adenocarcinoma.

The Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) intended to convert the accelerated approval granted to Tivdak (tisotumab vedotin-tftv) in 2021 to full approval for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.

Newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia had better outcomes when receiving Scemblix, compared with a different TKI, a study found.

When I received the news of colon cancer, I gained a new perspective on self-love and living life.

A small study of iopofosine I 131 in patients with pretreated Waldenstrom’s macroglobulinemia showed that the disease control rate was 100%.

More facilitation is needed to ensure that clinicians can connect patients with breast cancer to clinical trials they may be eligible for.

After being diagnosed with lymphoma, I decided to supplement my cancer treatment with turkey tail mushrooms.

Next-generation sequencing was more successful in finding patients with endometrial and colorectal cancer with dMMR disease, indicating that they were eligible for immunotherapy.

I hadn’t done aerobics in decades, but it was time to be off the cancer couch.

Recent research showed that Keytruda plus chemotherapy was superior to placebo plus chemotherapy in GI cancers, although the results were not considered statistically significant.

The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.

Wait for the other shoe to drop, or grab each day for all it’s worth?

Vd1-gd T cells, a rare type of immune cell, have been found to potentially predict how likely it is that certain patients with advanced skin cancer will be responsive to treatment via immunotherapy, according to recently published research.

After being diagnosed with a neuroendocrine cancer, I underwent seven phases of resiliency.

An expert stressed the importance of finding a patient support group and asking questions after being diagnosed with kidney — or any other form — of cancer.

A phase 1/2 trial evaluating seclidemstat plus Vidaza resumed patient enrollment for those with certain blood cancers and another phase 1/2 trial demonstrated improved results in patients with Ewing sarcomas.

A novel antibody drug conjugate was granted a Fast Track designation for certain patients with ovarian cancer.

Soon after experiencing headaches and other symptoms, I spoke up to my oncologist — and I’m glad I did.

From Shannen Doherty discussing in-vitro fertilization before breast cancer to "Chickadee" Cardwell's cancer experience to be featured on an upcoming TV series, here's what's happening in the oncology space this week.

An expert explained why chemotherapy-related amenorrhea in premenopausal women with breast cancer is “not just about having a period.”

As a comfort care companion for Moffitt Cancer Center, I sat vigil next to a dying patient with cancer with no family.

Patients with relapsed/refractory mantle cell lymphoma described by one expert as “older, sicker and more heavily pretreated” than those previously studied experienced impressive responses to treatment with CAR-T cell therapy Tecartus.

An expert discusses three crucial conversations about cancer care that patients should have with their health care providers.

Exploring holistic therapies can yield some interesting findings and benefits.

Researchers have found the CAR-T cell therapy Breyanzi (lisocabtagene maraleucel) to be a cost-effective second-line treatment for patients with relapsed and refractory diffuse large B-cell lymphoma as the drug’s cost rises.

The Food and Drug Administration approved Udenyca Onbody, an administration device for Udenyca, a biosimilar of Neulasta.

Buddha once said, “To keep the body in good health is a duty... otherwise we shall not be able to keep our mind strong and clear.”

A patient in a phase 2 trial has received the first dose of a novel cancer vaccine plus Keytruda for solid skin cancer tumors.

The first patients has been dosed within the new CLARIFY trial for patients with prostate cancer awaiting prostatectomy.